Structured evidence table for Ashwagandha Cognitive Performance Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Ashwagandha Cognitive Performance Meta-Analysis | Effects of Withania somnifera (L.) Dunal (Ashwagandha) on cognitive and physical function in adults: a systematic review and meta-analysis | 1 | Zhu X (2026) | Effects of Withania somnifera (L.) Dunal (Ashwagandha) on cognitive and physical function in adults: a systematic review and meta-analysis |
| Ashwagandha Cognitive Performance Meta-Analysis | These limitations have catalyzed an increased global focus on nutraceuticals and phytomedicines possessing multimodal biological activities that transcend mere monoamine reuptake inhibition. | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Ashwagandha Cognitive Performance Meta-Analysis | Unlike prior reviews that focus on individual herbs or broadly defined adaptogens, the present review integrates mechanistic, preclinical, and clinical evidence across these three agents to highlight their complementary rather than redundant actions. | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Ashwagandha Cognitive Performance Meta-Analysis | Rhodiola rosea Ginkgo biloba Withania somnifera A comprehensive and structured literature search was conducted to identify preclinical, translational, and clinical evidence related to the antidepressant effects and underlying neurobiological mechanisms of,, and(Ashwagandha). | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
| Ashwagandha Cognitive Performance Meta-Analysis | 1 2 3 Rhodiola rosea Ginkgo biloba Withania somnifera Depression constitutes one of the most incapacitating neuropsychiatric disorders globally (). | 3 | Li Xikun (2026) | Rhodiola rosea , Ginkgo biloba , and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders |
Source documents